Division of Breast Surgery, University of Nottingham, Nottingham, UK.
Ann Oncol. 2012 Jun;23(6):1465-71. doi: 10.1093/annonc/mdr446. Epub 2011 Oct 14.
A dedicated clinic for older women with early primary breast cancer, established in 1973, has recently evolved into a combined surgical/oncology facility. This study aimed to compare the clinical outcome across these periods.
From 1973 to 2010, 1758 women were managed. Analysis was carried out based on retrospective review and continued update of patient records.
In the recent decade, 56.3% had surgery, followed by primary endocrine therapy (PET; 41.1%) and primary radiotherapy (1.5%). Before 1999, 42.8%, 55.6% and 1% of patients had surgery, PET and primary radiotherapy, respectively. The use of adjuvant endocrine therapy and radiotherapy has increased from 33.6% to 54.9% and 5.8% to 34.6%, respectively. A significant improvement was seen in the annual rates of local (2.2% versus 0.5%, P < 0.001), regional (1.8% versus 0.4%, P < 0.001) and distant (2.9% versus 1.9%, P = 0.002) recurrences. Similarly, the 5-year breast cancer-specific and overall survival rates showed improvement [81% versus 91% (P < 0.001) and 56% versus 71% (P < 0.001), respectively].
In the recent decade, while surgery became the predominant treatment, a significant proportion of patients had non-operative therapies, selection of which was based on multidisciplinary assessment in the clinic. This management approach appears to produce excellent clinical outcome, which is significantly better than that in earlier period.
1973 年成立了一家专门为早期原发性乳腺癌老年女性服务的诊所,最近已发展为一家综合外科/肿瘤学中心。本研究旨在比较这两个时期的临床结果。
1973 年至 2010 年,共收治 1758 例患者。分析基于对患者病历的回顾性研究和持续更新。
在最近十年中,56.3%的患者接受了手术治疗,其次是原发性内分泌治疗(PET;41.1%)和原发性放疗(1.5%)。1999 年前,分别有 42.8%、55.6%和 1%的患者接受了手术、PET 和原发性放疗。辅助内分泌治疗和放疗的使用率从 33.6%增加到 54.9%和从 5.8%增加到 34.6%。局部(2.2%比 0.5%,P<0.001)、区域(1.8%比 0.4%,P<0.001)和远处(2.9%比 1.9%,P=0.002)复发的年发生率显著降低。同样,5 年乳腺癌特异性生存率和总生存率也有所提高[81%比 91%(P<0.001)和 56%比 71%(P<0.001)]。
在最近十年中,尽管手术成为主要治疗方法,但仍有相当一部分患者接受非手术治疗,治疗方案的选择是基于诊所的多学科评估。这种管理方法似乎产生了极好的临床结果,明显优于早期阶段。